More than 100 critically ill patients in NHS hospitals have received investigational treatment with Covid-19, an American pharmaceutical company said yesterday after leaking information suggesting it worked in global markets.
Gilead Sciences’ actions surged in New York after the release of images of a scientist describing patients who were recovering quickly after being treated with his antiviral remdesivir.
Dr. Kathleen Mullane, who is overseeing a trial of the drug at the University of Chicago, said that some critically ill patients had recovered quickly enough to be removed from respirators within 24 hours. Most did not need the full ten-day treatment. Out of 125 patients, only two had died.
“Most of our patients are severe and most go to